Close Menu

NEW YORK- Following the co-launch last month of its ctDx Lung targeted next-generation sequencing (NGS) liquid biopsy assay with the Laboratory Corporation of America, Resolution Bioscience is now engaged in discussions with HMOs and other private payors to secure commercial coverage for the test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.